Sign in

CIK 0001521036

  • Large accelerated filer

Lantheus Holdings, Inc.

Sign in to watch
Ticker
LNTH
Exchange
Nasdaq
Industry
In Vitro & In Vivo Diagnostic Substances
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
352318913
Phone
+1 978-671-8001
Business address
201 BURLINGTON ROAD, SOUTH BUILDING, BEDFORD, MA, 01730
Former names
Lantheus MI Holdings, Inc.
  1. 4 Planned sale President sold 2,000 shares at $79.65 ($159,300)
  2. 4 Planned sale Director sold 11,487 shares at an average $87.16 ($1,001,218)
  3. 4 Grant or award Director acquired 1,345 shares (grant or award)
  4. 3 Insider Initial Statement of Ownership
  5. 4 Shares withheld for taxes CFO and Treasurer gave up 786 shares (to pay taxes)
  6. 4 Planned sale Director sold 1,000 shares at $98.52 ($98,520)
  7. 4 Grant or award Chief Accounting Officer acquired 4,731 shares (grant or award)
  8. 4 Planned sale See Remarks sold 2,500 shares at $97.54 ($243,850)
  9. 4 Planned sale Director sold 15,500 shares at an average $96.48 ($1,495,396)
  10. 4 Planned sale President sold 2,000 shares at $96.39 ($192,780)
  11. 3 Insider Initial Statement of Ownership
  12. 4 Planned sale Director sold 10,481 shares at an average $95.50 ($1,000,900)
  13. 4 Shares withheld for taxes President gave up 518 shares (to pay taxes)
  14. 4 Planned sale Chief Accounting Officer sold 2,137 shares at an average $124.67 ($266,417)
  15. 4 Planned sale Director sold 12,530 shares at $95.04 ($1,190,851)
  16. 4 Grant or award Chief Medical Officer acquired 9,076 shares (grant or award)
  17. 4 Planned sale Chief Accounting Officer sold 341 shares at $79.77 ($27,202)
  18. 3 Insider Initial Statement of Ownership
  19. 4 Planned sale President sold 1,179 shares at $80.82 ($95,287)
  20. 4 Planned sale See Remarks sold 12,873 shares at $79.86 ($1,028,038)

Page 5 of 30 · 598 filings